Pharmaceutical giant Merck has announced a multi-target research and development collaboration with biotechnology startup Infinimmune. The deal, potentially worth up to $838 million, aims to utilize artificial intelligence (AI) to revolutionize the discovery and development of novel antibodies.
Strategic Highlights:
-
AI-Driven Platform: Merck will leverage Infinimmune’s proprietary AI platform, which analyzes vast libraries of human immune cells. This approach seeks to identify naturally occurring antibodies that offer improved safety and efficacy profiles compared to existing synthetic therapies.
-
Pipeline Diversification: The partnership strengthens Merck’s biologics capabilities, focusing on established immunology targets such as IL-22 and IL-13. These targets are critical for treating conditions like atopic dermatitis, IgA nephropathy, and ulcerative colitis.
-
Future-Proofing: This move is part of Merck’s broader strategy to expand beyond its oncology franchise and mitigate the upcoming revenue impact from the loss of exclusivity on its top-selling PD-1 inhibitor, Keytruda.
Agreement Details: Under the terms, Infinimmune is eligible for up to $838 million in upfront and milestone payments tied to the successful progression of antibody candidates. In exchange, Merck retains exclusive global rights to develop and commercialize any therapies emerging from the collaboration. This deal follows Merck’s recent acquisition of Terns Pharmaceuticals, highlighting the company’s aggressive pursuit of external early-stage innovation.